MINIMUM bio
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
81-83 Campbell St, Surry Hills, New Sout...Phone Number
+61 481880102Website
www.minimumbio.comRevenue
<$5 MillionIndustry
About MINIMUM bio
MINIMUM bio specializes in rapid and agnostic drug target identification through its innovative Mercurious® platform, which utilizes phage-displayed cDNA libraries to discover first-in-class drug targets in oncology, immunology, and longevity. The company focuses on building extensive libraries of rapamycin analogs (rapalogs) to identify targets and enhance drug development processes. Their technology allows for the identification of low-abundance proteins and provides primary target data within one to two weeks, significantly reducing costs compared to traditional methods. MINIMUM bio aims to partner with organizations to unlock value in drug discovery and access previously undruggable targets.Explore more
MINIMUM bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to MINIMUM bio
Compare insights from companies similar to MINIMUM bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2020
AB
Amelia BesharaCo-Founder & Director, Clinical Operations & Business Development
MINIMUM bio Tech Stack
A closer look at the technologies used by MINIMUM bio
See more technologies
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MINIMUM bio
Sign Up For FreeTo access detailed company insights
MINIMUM bio specializes in rapid and agnostic drug target identification through its innovative Mercurious® platform, which utilizes phage-displayed cDNA libraries to discover first-in-class drug targets in oncology, immunology, and longevity. The company focuses on building extensive libraries of rapamycin analogs (rapalogs) to identify targets an... Read More
